Date(s) - 21 Jun 2022
8:00 AM - 9:00 AM
Tuesday, June 21st, 2022 08:00 – 09:00 AM
- Tassos Gianakakos – CEO, MyoKardia
Please join us as Tassos discusses his journey from conception to acquisition. MyoKardia was acquired in 2021 by Bristol Myers Squibb for $13.5 Billion.
Location: Virtual via Zoom
About Our Speaker
Tassos is a driven executive and entrepreneur with a proven track-record of successfully starting and growing innovative, science-based companies in the biopharmaceutical industry. He’s a values-based leader who has built and developed extraordinary teams to take on the world’s most challenging health problems. Tassos has a passion for identifying and growing amazing leaders, bringing them together to create disruptive change in the field of medicine and improving health outcomes for society.
Since starting in vaccine research at Merck & Co. over 20 years ago, he has been instrumental in starting-up multiple biotechnology companies focused on creating game-changing therapies. Most recently, he was CEO of MyoKardia, a mission-driven company focused on changing the lives of people with serious cardiovascular disease through bold and innovative science. MyoKardia pioneered a precision medicine approach to discovering and development novel therapies for heart conditions and was acquired by BMS in October of 2021 for $13.5 billion.
Tassos and his wife Katina grew up in Chicago and currently live with their three boys in Paradise Valley. He has an engineering and economics degree from the Massachusetts Institute of Technology, a graduate degree in biotechnology from Northwestern University, and an MBA from Harvard Business School. Tassos is currently on the board of LianBio (NASDAQ: LIAN) a leading cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in Greater China and other Asian markets. He is a regular speaker at biotechnology industry events and as an alumni adviser to MIT, Northwestern and Harvard Business School.